Bio-Techne Corp. (TECH) is a publicly traded Healthcare sector company. As of July 8, 2026, TECH trades at $70.57 with a market cap of $11.05B and a P/E ratio of 99.41. TECH moved -0.07% today. Year to date, TECH is +19.43%; over the trailing twelve months it is +37.01%. Its 52-week range spans $43.20 to $79.28. Analyst consensus is neutral with an average price target of $66.09. Rallies surfaces TECH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Bio-Techne Unveils Five AI-Engineered Heat-Stable Growth Factors, Hyperactive Cytokines: Bio-Techne launched five new AI-engineered proteins—FGF-4, FGF-7 and FGF-8b heat-stable growth factors plus IL-3 heat-stable and IL-15 hyperactive cytokines—to its R&D Systems portfolio, aiming to boost stability, activity and scalability in advanced cell culture and cell therapy workflows. Early adopters report enhanced cell expansion and lower manufacturing costs.
| Metric | Value |
|---|---|
| Price | $70.57 |
| Market Cap | $11.05B |
| P/E Ratio | 99.41 |
| EPS | $0.71 |
| Dividend Yield | 0.08% |
| 52-Week High | $79.28 |
| 52-Week Low | $43.20 |
| Volume | 1.46M |
| Avg Volume | 0 |
| Revenue (TTM) | $1.21B |
| Net Income | $109.56M |
| Gross Margin | 64.96% |
14 analysts cover TECH: 0 strong buy, 2 buy, 12 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $66.09.